

	Units	Attack MY, first LP/event	Remission MY, last LP/event	Attack ON, first LP/event	Remission ON, last LP/event	Attack BRAIN, first LP/event	Remission BRAIN, last LP/event
Pleocytosis	<i>samples</i>	32/40 (80%)	1/6 (16.7%)	15/50 (30%)	0/6 (0%)	6/10 (60%)	1/3 (33.3%)
WCC	<i>cells/μl</i>	31.5 (1-463;40)	1.5 (0-13;6)	3 (0-135;48)	1 (0-3;5)	13.5 (0-68;10)	3 (1-16;3)
WCC >100/ μ l	<i>samples</i>	12/40 (30%)	0/6 (0%)	1/49 (2%)	0/6 (0%)	0/10 (0%)	0/3 (0%)
OCB	<i>samples</i>	3/37 (8.1%)	1/6 (16.7%)	3/48 (6.3%)	0/6 (0%)	2/10 (20%)	0/3 (0%)
IgG-IF >10%	<i>samples</i>	2/35 (5.7%)	0/6 (0%)	2/40 (5%)	0/4 (0%)	0/8 (0%)	0/3 (0%)
QAlb > Qlim(Alb)	<i>samples</i>	22/36 (61.1%)	2/6 (33.3%)	15/43 (34.9%)	1/4 (25%)	4/8 (50%)	0/3 (0%)
CSF TP elevated	<i>samples</i>	21/37 (56.8%)	1/6 (16.7%)	15/47 (31.9%)	1/6 (16.7%)	6/8 (75%)	1/3 (33.3%)
CSF TP concentrations	<i>mg/dl</i>	59.5 (20.5-176;34)	31.05 (5.11-48.2;6)	37.4 (20.8-171.8;43)	37.85 (32-59.8;4)	48.2 (30.4-74.2;8)	40 (20-47;3)
CSF TP >100 mg/dl	<i>samples</i>	6/37 (16.2%)	0/6 (0%)	1/47 (2.1%)	0/6 (0%)	0/8 (0%)	0/3 (0%)
CSF L-lactate elevated	<i>samples</i>	10/26 (38.5%)	0/4 (0%)	6/36 (16.7%)	0/4 (0%)	0/3 (0%)	0/2 (0%)
CSF L-lactate concentrations	<i>mg/dl</i>	2.14 (1.12-4.43;24)	1.45 (1.4-1.9;4)	1.7 (1.05-2.68;35)	1.7 (1.44-1.74;3)	1.51 (1.5-1.7;3)	1.51 (1.33-1.69;2)
CSF L-lactate >3 mmol/l	<i>samples</i>	4/26 (15.4%)	0/4 (0%)	0/36 (0%)	0/4 (0%)	0/3 (0%)	0/2 (0%)
Time since attack onset	<i>days</i>	7 (0-31;41)	380.5 (119-3664;6)	8.5 (0-34;50)	154 (97-275;6)	14 (0-24;11)	191 (117-2624;3)

Supplementary Table 1. CSF findings during acute attacks and during remission in the ‘acute MY subgroup’, the ‘acute ON subgroup’ and the ‘acute BRAIN subgroup’ (stratified results from Table 11). BRAIN = brain/brainstem/cerebellar subgroup; CSF = cerebrospinal fluid; IgG-IF = intrathecally produced CSF immunoglobulin G fraction; LP = lumbar puncture; MY = myelitis subgroup; ON = optic neuritis subgroup; QAlb = albumin CSF/serum ratio; TP = total protein; WCC = white cell count.